mutLBSgeneDB |
Gene summary for LGALS2 |
Gene summary |
Basic gene Info. | Gene symbol | LGALS2 |
Gene name | lectin, galactoside-binding, soluble, 2 | |
Synonyms | HL14 | |
Cytomap | UCSC genome browser: 22q13.1 | |
Type of gene | protein-coding | |
RefGenes | NM_006498.2, | |
Description | S-Lac lectin 2beta-galactoside-binding lectin L-14-IIgal-2galectin 2galectin-2lactose-binding lectin 2 | |
Modification date | 20141207 | |
dbXrefs | MIM : 150571 | |
HGNC : HGNC | ||
Ensembl : ENSG00000100079 | ||
HPRD : 08859 | ||
Vega : OTTHUMG00000150590 | ||
Protein | UniProt: P05162 go to UniProt's Cross Reference DB Table | |
Expression | CleanEX: HS_LGALS2 | |
BioGPS: 3957 | ||
Pathway | NCI Pathway Interaction Database: LGALS2 | |
KEGG: LGALS2 | ||
REACTOME: LGALS2 | ||
Pathway Commons: LGALS2 | ||
Context | iHOP: LGALS2 | |
ligand binding site mutation search in PubMed: LGALS2 | ||
UCL Cancer Institute: LGALS2 | ||
Assigned class in mutLBSgeneDB | C: This gene just belongs to mutLBSgenes. |
Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
GO ID | GO Term | PubMed ID |
Top |
Ligand binding site mutations for LGALS2 |
Cancer type specific mutLBS sorted by frequency |
LBS | AAchange of nsSNV | Cancer type | # samples | R49 | F50I | LUAD | 1 | R70,E68 | Q69E | OV | 1 | H45 | H45Y | STAD | 1 |
cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
Top |
Protein structure related information for LGALS2 |
Relative protein structure stability change (ΔΔE) using Mupro 1.1 Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
: nsSNV at non-LBS: nsSNV at LBS |
nsSNVs sorted by the relative stability change of protein structure by each mutation Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
LBS | AAchange of nsSNV | Relative stability change | H45 | H45Y | -0.96123499 | R49 | F50I | -0.83763188 | E68 | Q69E | -0.50540255 | R70 | Q69E | -0.50540255 |
(MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
Structure image for LGALS2 from PDB |
Top |
Differential gene expression and gene-gene network for LGALS2 |
Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types |
Differential co-expressed gene network based on protein-protein interaction data (CePIN) |
Top |
Top |
Phenotype information for LGALS2 |
Gene level disease information (DisGeNet) |
Disease ID | Disease name | # PubMed | Association type |
umls:C0027051 | Myocardial Infarction | 14 | Biomarker, GeneticVariation |
umls:C0520459 | Enterocolitis, Necrotizing | 1 | Biomarker |
Mutation level pathogenic information (ClinVar annotation) |
Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
Top |
Pharmacological information for LGALS2 |
Gene expression profile of anticancer drug treated cell-lines (CCLE) Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient. |
Gene-centered drug-gene interaction network |
Drug information targeting mutLBSgene (Approved drugs only) |
Drug status | DrugBank ID | Name | Type | Drug structure |
Experimental | DB02379 | Beta-D-Glucose | Small molecule |
Gene-centered ligand-gene interaction network |
Ligands binding to mutated ligand binding site of LGALS2 go to BioLip |
Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS | GAL | BETA-D-GALACTOSE | 1hlc | A | H45 R49 E68 | GAL | BETA-D-GALACTOSE | 1hlc | B | H45 R49 E68 | BGC | BETA-D-GLUCOSE | 1hlc | A | R49 E68 R70 | BGC | BETA-D-GLUCOSE | 1hlc | B | R49 E68 R70 |
Top |
Conservation information for LBS of LGALS2 |
Multiple alignments for P05162 in multiple species |
LBS | AA sequence | # species | Species | E68 | SNWGQEQREDH | 1 | Homo sapiens | E68 | GRWGQEQRENH | 1 | Mus musculus | E68 | SSWGQEQRENH | 1 | Rattus norvegicus | H45 | ETLNLHFNPRF | 2 | Mus musculus, Rattus norvegicus | H45 | DKLNLHFNPRF | 1 | Homo sapiens | N47 | LNLHFNPRFSE | 1 | Homo sapiens | N47 | LNLHFNPRFDE | 1 | Mus musculus | N47 | LNLHFNPRFNE | 1 | Rattus norvegicus | N58 | STIVCNSLDGS | 1 | Homo sapiens | N58 | STIVCNTSEGG | 1 | Mus musculus | N58 | STIVCNTLDGS | 1 | Rattus norvegicus | R120 | SYLSVRGGFNM | 1 | Homo sapiens | R120 | HYLSM-GGLQI | 1 | Mus musculus | R120 | RYLSM-DGLQI | 1 | Rattus norvegicus | R49 | LHFNPRFSEST | 1 | Homo sapiens | R49 | LHFNPRFDEST | 1 | Mus musculus | R49 | LHFNPRFNEST | 1 | Rattus norvegicus | R70 | WGQEQREDHLC | 1 | Homo sapiens | R70 | WGQEQRENHMC | 1 | Mus musculus | R70 | WGQEQRENHSC | 1 | Rattus norvegicus | W65 | LDGSNWGQEQR | 1 | Homo sapiens | W65 | SEGGRWGQEQR | 1 | Mus musculus | W65 | LDGSSWGQEQR | 1 | Rattus norvegicus |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |